Clene isasama ang mga pagsusuri ng ALS biomarker sa NDA para sa accelerated approval

Inilalantad ng 8-K na isasama ng Clene ang mga bagong pagsusuri ng biomarker sa paghahain ng NDA nito para sa CNM-Au8 sa ALS, na malinaw na sumusuporta sa accelerated-approval pathway. Walang PDUFA date, advisory-committee date, o topline readout na nakasaad; ang filing mismo ang milestone.

Mahahalagang fact

Na-file: Ago 10, 2026, 12:07 PM
Kaganapan: Naisumite ang aplikasyon
Direksyon: Neutral
Kumpanya: CLNNClene
Asset: CNM-Au8
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

clnn20260806_8k.htm false 0001822791 0001822791 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Petsa ng Ulat (Petsa ng pinakamaagang naiulat na kaganapan): August 10, 2026 CLENE INC. (Exact name of registrant as specified in its charter) Delaware 001-39834 85-2828339 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.) 6550 South Millrock Drive , Suite G50 Salt Lake City , Utah 84121 (Address of principal executive offices) (Zip Code) ( 801 ) 676-9695 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.

SEC 8-K